evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,835 questions · 1,886 findings · 74 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Tacrolimus 0.03% vs pimecrolimus 1%

Physician's assessment of global response of improvement · people with atopic dermatitis

Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Tacrolimus 0.03% vs pimecrolimus 1%

Adverse effects ‐ application site reaction · people with atopic dermatitis

Tacrolimus 0.03% showed no clear difference in adverse effects ‐ application site reaction compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Tacrolimus 0.1% vs corticosteroids

Adverse effects ‐ burning · people with atopic dermatitis

Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).

3 findings from 1 review

Tacrolimus 0.1% vs corticosteroids

Participant's self‐assessment of global response of improvement · people with atopic dermatitis

Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).

1 finding from 1 review

Tacrolimus 0.1% vs pimecrolimus 1%

Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis

Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with pimecrolimus 1% (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs pimecrolimus 1%

Adverse effects ‐ 6 weeks · people with atopic dermatitis

It is very uncertain whether tacrolimus 0.1% changes adverse effects ‐ 6 weeks compared with pimecrolimus 1% (very low certainty).

1 finding from 1 review

Etanercept vs placebo

Percentage of participants reaching PASI 75 · people with paediatric psoriasis

Etanercept leads to higher PASI 75 Participants achieving a 75% improvement in the Psoriasis… compared with placebo (high certainty).

1 finding from 1 review

Etanercept vs placebo

PASI 50 · people with paediatric psoriasis

Etanercept leads to higher PASI 50 Participants achieving a 50% improvement in the Psoriasis… compared with placebo (high certainty).

1 finding from 1 review

Etanercept vs placebo

PASI 90 · people with paediatric psoriasis

Etanercept leads to higher PASI 90 Participants achieving a 90% improvement in the Psoriasis… compared with placebo (high certainty).

1 finding from 1 review

Etanercept vs placebo

PGA Participants achieving a PGA of 'clear' or 'almost clear' · people with paediatric psoriasis

Etanercept leads to higher PGA Participants achieving a PGA of 'clear' or 'almost clear' compared with placebo (high certainty).

1 finding from 1 review

Etanercept vs placebo

CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis
1 finding from 1 review

Adalimumab every other week vs placebo

Treatment discontinuation · participants with hidradenitis suppurativa

Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).

1 finding from 1 review

Adalimumab every other week vs placebo

Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa

Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).

1 finding from 1 review